2003
DOI: 10.1590/s0036-46652003000700008
|View full text |Cite
|
Sign up to set email alerts
|

Chemotherapy

Abstract: Miltefosine, initially developed as an anti-tumor agent, is the newest drug for the treatment of visceral leishmaniasis. Several laboratories have shown that this ether-lipid analogue is also toxic against different forms of T. cruzi, but its mechanism(s) of action is(are) still unclear. In leukemic cells, Miltefosine seems to interfere with cellular signal transduction pathways by inhibition of protein kinase C (PKC) and Na + , K + -ATPase. In order to verify if Miltefosine is able to act in a similar way on … Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles